EASL

EASL
June 05-08, 2024
Milan, Italy

European Association for the Study of Liver Disease .

Explore more information for Gilead Liver Diseases therapies
Material Type
Filter by Keyword(s)

Filter results with keywords such as:

  • Name of author(s)
  • Disease state
  • Indication
  • Trial phase
  • Trial name
  • Trial date

Note: Multiple keywords can be applied at the same time.

    Results (16)

    Bulevirtide in combination with pegylated interferon alfa-2a shows a sustained off-treatment response in the liver

    • Author(s): Allweiss, L
    • bulevirtide
    • Liver Diseases

    Long-term efficacy and safety of open-label seladelpar treatment in patients with primary biliary cholangitis (PBC): Interim results for 2 years from the ASSURE study

    • Author(s): Palak, J
    • seladelpar
    • Liver Diseases

    Improvement in liver histology is observed in most patients with chronic hepatitis delta after 48 weeks of bulevirtide monotherapy.

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases

    Undetectable HDV RNA at 24 Weeks of Treatment With Bulevirtide and Pegylated Interferon Alfa-2a Combination Therapy Is an Important Predictor of Maintained Response Off-Therapy

    • Author(s): Zoulim, F
    • bulevirtide
    • Liver Diseases

    The burden of chronic hepatitis delta in Italy: potential impacts and effects of bulevirtide through cost of illness and cost consequence analysis

    • Author(s): Marcellusi, A
    • bulevirtide
    • Liver Diseases

    Differential expression and sequence variants of sodium taurocholate cotransporting polypeptide (NTCP) do not affect HDV inhibition by Bulevirtide (BLV)

    • Author(s): Xu, S
    • bulevirtide
    • Liver Diseases

    Intrahepatic sodium taurocholate co-transporting polypeptide gene transcript and membrane-localized protein expression changes in chronic hepatitis D patients following 48 weeks of treatment with Bulevirtide

    • Author(s): Nieves,W
    • bulevirtide
    • Liver Diseases

    No Amino Acid Substitution in HBV Pres1, HDAg, Or NTCP Associated With Suboptimal Response to Bulevirtide in Combination With Pegylated Interferon Alfa-2a Treatment in Participants With Chronic Hepatitis Delta: Results From MYR204, a Phase 2b Study

    • Author(s): Liu, Y
    • bulevirtide
    • Liver Diseases

    Efficacy and Safety of 144 Weeks of Bulevirtide 2 mg or 10 mg monotherapy from the ongoing Phase 3 study, MYR301

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases

    48-Week Off-Therapy Efficacy and Safety of Bulevirtide in Combination with Pegylated Interferon Alfa-2a in Patients with Chronic Hepatitis Delta: Final Results from the Phase 2b, Open-Label, Randomised, Multicentre Study MYR204

    • Author(s): Asselah, T
    • bulevirtide
    • Liver Diseases

    Impact of bulevirtide given with or without nucleos(t)ide analogues on 48-week virologic outcomes in patients with chronic hepatitis delta virus infection

    • Author(s): Lampertico, P
    • bulevirtide
    • Liver Diseases

    Undetectable HDV RNA Defined as Target Not Detected at the End of Treatment With Bulevirtide and/or Pegylated Interferon Alpha-2a Is an Important Predictor of 48 Weeks Sustained Virologic Response in Chronic Hepatitis Delta

    • Author(s): Zoulim, F
    • bulevirtide
    • Liver Diseases

    Use of proton pump inhibitors among German Hepatitis C patients treated with sofosbuvir/velpatasvir: Data from the German Hepatitis C-Registry (2016-2022)

    • Author(s): Cornberg, M
    • epclusa
    • Liver Diseases

    Description of age, sex, and characteristics of Hepatitis C patients in the SVR10K study: A real-world SOF/VEL analysis performed across five global regions

    • Author(s): Aleman, S
    • epclusa
    • Liver Diseases

    Tenofovir-based antiviral therapy reduces long-term incidence of hepatocellular carcinoma in chronic hepatitis B

    • Author(s): Kim, W Ray
    • biktarvy
    • Liver Diseases

    Off-treatment outcomes after discontinuing tenofovir-based treatment in hepatitis B e antigen-positive and hepatitis B e antigen-negative patients with chronic hepatitis B virus

    • Author(s): Buti, M
    • biktarvy
    • Liver Diseases